Pirfenidone attenuates the IL-1β-induced hyaluronic acid increase in orbital fibroblasts from patients with thyroid-associated ophthalmopathy

Investigative Ophthalmology and Visual Science

Volumn 55, Issue 4, 2014, Pages 2276-2283

  Chung, Seung Ah ^a   Jeon, Bo Kyung ^b   Choi, Youn Hee ^b   Back, Keum Ok ^a   Lee, Jong Bok ^c   Kook, Koung Hoon ^a  

^a Ajou University School of Medicine   (South Korea)

^b Ewha Womans University School of Medicine   (South Korea)

^c Yonsei University College of Medicine   (South Korea)

Author keywords

Hyaluronic acid; Hyaluronic acid synthase; IL 1 ; Mitogenactivated protein kinase; Orbital fibroblast; Pirfenidone; Thyroid associated ophthalmopathy

Indexed keywords

DEXAMETHASONE; HYALURONIC ACID; INTERLEUKIN 1BETA; MITOGEN ACTIVATED PROTEIN KINASE; PIRFENIDONE; SYNAPTOPHYSIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA BINDING; ENDOCRINE OPHTHALMOPATHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROBLAST CULTURE; GEL MOBILITY SHIFT ASSAY; HUMAN; HUMAN CELL; MALE; MIDDLE AGED; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

HYALURONIC ACID; HYALURONIC ACID SYNTHASE; IL-1Β; MITOGEN-ACTIVATED PROTEIN KINASE; ORBITAL FIBROBLAST; PIRFENIDONE; THYROID-ASSOCIATED OPHTHALMOPATHY;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BLOTTING, WESTERN; CELLS, CULTURED; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROBLASTS; GENE EXPRESSION REGULATION; GLUCURONOSYLTRANSFERASE; GRAVES OPHTHALMOPATHY; HUMANS; HYALURONIC ACID; INTERLEUKIN-1BETA; MALE; MIDDLE AGED; PYRIDONES; REAL-TIME POLYMERASE CHAIN REACTION; RNA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84898467247     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.13-13759     Document Type: Article

References (34)

1. Naik VM, Naik MN, Goldberg RA, Smith TJ, Douglas RS. Immunopathogenesis of thyroid eye disease: emerging paradigms. Surv Ophthalmol. 2010;55:215-226.
2. Kazim M, Goldberg RA, Smith TJ. Insights into the pathogenesis of thyroid-associated orbitopathy: evolving rationale for therapy. Arch Ophthalmol. 2002;120:380-386.
3. Smith TJ, Bahn RS, Gorman CA. Connective tissue, glycosaminoglycans, and diseases of the thyroid. Endocr Rev. 1989;10: 366-391.
4. Hufnagel TJ, Hickey WF, Cobbs WH, Jakobiec FA, Iwamoto T, Eagle RC. Immunohistochemical and ultrastructural studies on the exenterated orbital tissues of a patient with Graves' disease. Ophthalmology. 1984;91:1411-1419.
5. Kaback LA, Smith TJ. Expression of hyaluronan synthase messenger ribonucleic acids and their induction by interleukin-1beta in human orbital fibroblasts: potential insight into the molecular pathogenesis of thyroid-associated ophthalmopathy. J Clin Endocrinol Metab. 1999;84:4079-4084.
6. Smith TJ. Novel aspects of orbital fibroblast pathology. J Endocrinol Invest. 2004;27:246-253.
7. Smith TJ. Orbital fibroblasts exhibit a novel pattern of responses to proinflammatory cytokines: potential basis for the pathogenesis of thyroid-associated ophthalmopathy. Thyroid. 2002;12:197-203.
8. Smith TJ, Wang HS, Evans CH. Leukoregulin is a potent inducer of hyaluronan synthesis in cultured human orbital fibroblasts. Am J Physiol. 1995;268:C382-C388.
9. Wong YK, Tang KT, Wu JC, Hwang JJ, Wang HS. Stimulation of hyaluronan synthesis by interleukin-1beta involves activation of protein kinase C betaII in fibroblasts from patients with Graves' ophthalmopathy. J Cell Biochem. 2001;82:58-67.
10. Wang HS, Tung WH, Tang KT, et al. TGF-beta induced hyaluronan synthesis in orbital fibroblasts involves protein kinase C betaII activation in vitro. J Cell Biochem. 2005;95: 256-267.
11. Smith TJ, Hoa N. Immunoglobulins from patients with Graves' disease induce hyaluronan synthesis in their orbital fibroblasts through the self-antigen, insulin-like growth factor-I receptor. J Clin Endocrinol Metab. 2004;89:5076-5080.
12. Bartalena L, Baldeschi L, Dickinson A, et al. Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol. 2008; 158:273-285.
13. Kehrer JP, Margolin SB. Pirfenidone diminishes cyclophosphamide-induced lung fibrosis in mice. Toxicol Lett. 1997;90:125-132.
14. Di Sario A, Bendia E, Macarri G, et al. The anti-fibrotic effect of pirfenidone in rat liver fibrosis is mediated by downregulation of procollagen α1(I), TIMP-1 and MMP-2. Dig Liver Dis. 2004; 36:744-751.
15. Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011;377:1760-1769.
16. Kim H, Choi YH, Park SJ, et al. Antifibrotic effect of pirfenidone on orbital fibroblasts of patients with thyroidassociated ophthalmopathy by decreasing TIMP-1 and collagen levels. Invest Ophthalmol Vis Sci. 2010;51:3061-3066.
17. Spond J, Case N, Chapman RW, et al. Inhibition of experimental acute pulmonary inflammation by pirfenidone. Pulm Pharmacol Ther. 2003;16:207-214.
18. Nakanishi H, Kaibori M, Teshima S, et al. Pirfenidone inhibits the induction of iNOS stimulated by interleukin-1beta at a step of NF-kappaB DNA binding in hepatocytes. J Hepatol. 2004; 41:730-736.
19. Choi YH, Back KO, Kim HJ, Lee SY, Kook KH. Pirfenidone attenuates IL-1beta-induced COX-2 and PGE2 production in orbital fibroblasts through suppression of NF-kappaB activity. Exp Eye Res. 2013;113:1-8.
20. Choi YH, Bernardi R, Pandolfi PP, Benveniste EN. The promyelocytic leukemia protein functions as a negative regulator of IFN-gamma signaling. Proc Natl Acad Sci U S A. 2006;103:18715-18720.
21. Weigel PH, Hascall VC, Tammi M. Hyaluronan synthases. J Biol Chem. 1997;272:13997-14000.
22. Itano N, Sawai T, Yoshida M, et al. Three isoforms of mammalian hyaluronan synthases have distinct enzymatic properties. J Biol Chem. 1999;274:25085-25092.
23. Chen B, Tsui S, Smith TJ. IL-1 beta induces IL-6 expression in human orbital fibroblasts: identification of an anatomic-site specific phenotypic attribute relevant to thyroid-associated ophthalmopathy. J Immunol. 2005;175:1310-1319.
24. Han R, Tsui S, Smith TJ. Up-regulation of prostaglandin E2 synthesis by interleukin-1beta in human orbital fibroblasts involves coordinate induction of prostaglandin-endoperoxide H synthase-2 and glutathione-dependent prostaglandin E2 synthase expression. J Biol Chem. 2002;277:16355-16364.
25. Li L, Asteriou T, Bernert B, Heldin CH, Heldin P. Growth factor regulation of hyaluronan synthesis and degradation in human dermal fibroblasts: importance of hyaluronan for the mitogenic response of PDGF-BB. Biochem J. 2007;404:327-336.
26. de la Motte CA. Hyaluronan in intestinal homeostasis and inflammation: implications for fibrosis. Am J Physiol Gastrointest Liver Physiol. 2011;301:G945-G949.
27. Stuhlmeier KM. Effects of leflunomide on hyaluronan synthases (HAS): NF-kappa B-independent suppression of IL-1-induced HAS1 transcription by leflunomide. J Immunol. 2005;174: 7376-7382.
28. Paik JS, Cho WK, Oh EH, Lee SB, Yang SW. Palmitate induced secretion of IL-6 and MCP-1 in orbital fibroblasts derived from patients with thyroid-associated ophthalmopathy. Mol Vis. 2012;18:1467-1477.
29. David-Raoudi M, Deschrevel B, Leclercq S, Galera P, Boumediene K, Pujol JP. Chondroitin sulfate increases hyaluronan production by human synoviocytes through differential regulation of hyaluronan synthases: role of p38 and Akt. Arthritis Rheum. 2009;60:760-770.
30. Ducale AE, Ward SI, Dechert T, Yager DR. Regulation of hyaluronan synthase-2 expression in human intestinal mesenchymal cells: mechanisms of interleukin-1beta-mediated induction. Am J Physiol Gastrointest Liver Physiol. 2005;289: G462-G470.
31. Azuma A. Pirfenidone treatment of idiopathic pulmonary fibrosis. Ther Adv Respir Dis. 2012;6:107-114.
32. Carter NJ. Pirfenidone: in idiopathic pulmonary fibrosis. Drugs. 2011;71:1721-1732.
33. Richeldi L, du Bois RM. Pirfenidone in idiopathic pulmonary fibrosis: the CAPACITY program. Expert Rev Respir Med. 2011;5:473-481.
34. Vigetti D, Genasetti A, Karousou E, et al. Proinflammatory cytokines induce hyaluronan synthesis and monocyte adhesion in human endothelial cells through hyaluronan synthase 2 (HAS2) and the nuclear factor-kappaB (NF-kappaB) pathway. J Biol Chem. 2010;285:24639-24645.